121 results about "Epitope vaccine" patented technology

The invention discloses a foot-and-mouth disease genetic engineering mixed epitope vaccine and a preparation method thereof. The vaccine consists of the following four parts: a serial B cell epitope recombinant protein BI consisting of main neutralizing epitops of O-type foot-and-mouth disease viruses in Cathay, Transasia and Mya 98 pedigrees with a gene sequence of SEQ ID NO:1 and an amino acid sequence of SEQ ID NO:2, a T-cell epitope recombinant protein TI consisting of serial connection of universal T-cell epitope and a plurality of foot-and-mouth disease virus specific T-cell epitopes with a gene sequence of SEQ ID NO:3 and an amino acid sequence of SEQ ID NO:4, Toll-like receptor 3 agonist-polyinosinic acid-polycytidysic acid and/or Toll-like receptor7/8 agonist-R848 serving as immunopotentiator, and 201 oil adjuvant. When being used for immunizing a pig, the BI and TI mixed epitope vaccine prepared by utilizing the method can produce a protective immunization effect the same as or better than that of an inactivated influenza virus Vaccines, and has a cross protection effect to viruses of the three pedigrees, so that the vaccine is a novel immune-enhanced O-type foot-and-mouth genetic engineering mixed epitope vaccine.

The invention relates to a selection method for epitope which can stimulate the protective immune response of the body anti-mycobacterium tuberculosis and the function thereof, in particular to the molecule mimic peptide of the epitope with vaccine development prospect from the mycobacterium tuberculosis and the coding DNA thereof. The selection method of epitope which can stimulate the protective immune response of the body anti-mycobacterium tuberculosis and the function thereof provides T lymphocyte epitope contained in one important gene Ag85B in the research of mycobacterium tuberculosis and the method of deducting or selecting the epitope, which is beneficial to further developing novel multivalent and poly epitope tuberculosis vaccine and prevent and control the happening and development of tuberculosis; the method makes a foundation of the future development of synthesizing peptide vaccine epitope vaccine and dna vaccine by using epitope and provides molecule mimic peptide of epitope which can stimulate the protective immune response of the body anti-mycobacterium tuberculosis and the peptide has the amino acid sequence of FVRSSNLKFQDAYNA(SEQ ID NO:1).

The invention relates to an epitope peptide H362 of an HN protein in PPRV, and determination, a preparation method and application thereof. The amino acid sequence of the epitope peptide is H362: <362>EANWVVPSTDVRDL<375>. The invention detects reactogenicity of a monoclonal antibody and PPRV and specificity of the monoclonal antibody; according to detection results, the monoclonal antibody has good reactogenicity to rPPRV-HN-F protein; immunoinformatic technology is cooperatively used for predicating the B cell epitope of the HN protein; an aminated ELISA plate is employed for detecting candidate epitopes and the monoclonal antibody 10E3, and the epitope peptide H362 corresponding to 10E3 is determined; and determination of the epitope peptide lays a theoretical foundation for preparation of epitope vaccine antigens and diagnostic reagent antigens for PPRV.

The invention provides three Th cell epitope peptide and code DNA of pylorus spirillum urease B subunit, also providing a bacterin of B cell epitope which contains the triepitope peptide and an additional urease B subunit. Among them, the epitope peptide is the polypeptide which has one of the amino acid residue sequences as follows: 1) hasing amino acid sequence of sequence 2, sequence3 and sequence 7 in sequence table; 2) replacing, deleting or appending the amino acid sequence of sequence 2, sequence3 and sequence 7 in sequence table by one or several amino acid residue to form derivanting polypeptide. The coded DNA is one of the following sequences: 1) hasing the ribonucleotide sequence of sequence 8, sequence 9 and sequence sequence 10 table. 2) Hasing the ribonucleotide sequence of same coded product with sequence 8, sequence 9 and sequence10 in sequence table. The epitope vaccine which contains the polypeptide of this invention has the protein vaccine of amino acid sequence in sequence 12 of sequence table. The vaccine or medication which is made by using the polypeptide of the invention as active component can clean out the infection caused by pylorus spirillum and has wide application prospect in medical realm.

The invention discloses a CTL (Cytotoxic T Lymphocyte) epitope peptide of a foot-and-mouth disease virus type O as well as a screening method and application of the CTL epitope peptide. The CTL epitope peptide is composed of nine amino acid residues, and the amino acid sequence of the CTL epitope peptide is as follows: Ala-Thr-Arg-Val-Thr-Glu-Leu-Leu-Tyr. The epitope peptide has relatively strong combining capacity with SLA (Swineleukocyteantigen)-I proteins from various strains of swine and can induce cytotoxic immune response so as to be suitable for preparing vaccines for preventing and controlling foot-and-mouth disease viruses of various strains of swine and wide in application range. According to the invention, a CTL simulated epitope peptide of a foot-and-mouth disease virus is combined with a single-chain molecule of SLA-I of six strains of constructed swine in vitro, thus a polypeptide which can be combined with a complex can be screened through mass spectrum measurement; in addition, a simulated epitope peptide which can be induced to generate the immune response capacity of T cells is determined through ELISPOT (Enzyme-Linked Immunospot Assay) detection. The invention provides a method for screening and authenticating the CTL epitope of the foot-and-mouth disease virus in a large scale, and lays the foundation for researching and preparing a multi-epitope vaccine of a foot-and-mouth disease.

The invention provides a helicobacter pylori epitope vaccine. The active constituent of the helicobacter pylori epitope vaccine is a polypeptide and mainly consists of a cholera toxin B subunit and a B cell antigen epitope from a urease A subunit. A preparation method of the helicobacter pylori epitope vaccine comprises the following steps of: synthesizing the nucleotide sequence of the B cell antigen epitope from the urease A subunit by a PCR (polymerase chain reaction) technology, coupling the nucleotide sequence with the gene sequence of the cholera toxin B subunit to form into a fusion gene, and expressing the fusion gene in the escherichia coli by an expression vector to obtain the fusion protein of the epitope vaccine by means of protein purification. The helicobacter pylori epitope vaccine can be used for inducing the human body to generate an epitope specific antibody which is higher in titer to the urease. In the biologic medical field, the epitope vaccine can be used for preventing and curing the relevant diseases caused by the helicobacter pylori infection, thereby being great in economic benefit and social benefit.

The invention discloses a bovine A-type foot-and-mouth disease multi-epitope recombinant vaccine, and a preparation method and an application thereof, and belongs to the field of veterinary vaccine research. The preparation method comprises the following steps: carrying out reasonable serial connection on the dominant antigen epitopes of bovine A-type foot-and-mouth disease virus representative strains once pandemic in China by adopting an antigenized antibody strategy and a brand new reverse vaccinology technology and strategy, coupling with a bovine IgG immunostimulatory fragment (IgG heavy chain constant region), cloning into a prokaryotic expression vector to construct a recombinant expression vector, transforming Escherichia coli cells to express a recombinant antigen, purifying by adopting Ni-NAT column chromatography, quantifying by a Bio-Rad protein quantification kit, and preparing the vaccine individually or combining with a recombinant foot-and-mouth disease virus 3D protein. A result of animal immune experiments shows that the recombinant protein or combined vaccine can stimulate the body to produce a protective antibody with high titer and also can protect immune animals against a virus attack, so the bovine A-type foot-and-mouth disease multi-epitope recombinant vaccine has a good application prospect.

The invention relates to a DC-based HCV epitope vaccine and a preparation method thereof. The preparation method comprises 1, carrying out CD34<+> and/or CD14<+> cell induced culture to obtain immature DC, 2, adding linear polypeptide comprising HCVNS3 and HCVNS5 polypeptide chains into the immature DC and carrying out co-culture, and 3, adding a tumor necrosis factor-alpha and interleukin or lipopolysaccharide into the culture and carrying out culture for 7-13 days until the DC is mature. The DC-based HCV epitope vaccine has stable properties and strong immunogenicity and can well adjust a HCV virus-resistant body immunization mechanism.

The invention relates to a helicobacter pylori multiple-epitope fusion protein and a multiple-epitope vaccine prepared by the helicobacter pylori multiple-epitope fusion protein. An amino acid sequence of the helicobacter pylori multiple-epitope fusion protein is shown as SEQ ID NO:1. Fusion proteins in the multiple-epitope vaccine can induce generation of specificity sIgA in stomach tissues and formation of phigh-potency specificity IgG in blood serum, can effectively reduce constant value quantity of helicobacter pylori in a stomach of a mouse and has obvious protection effects.

The invention discloses an EGFR and HER2 combined polypeptide epitope vaccine; two B cell epitope mimic polypeptide I and II of HER2 of the HER family, and a B cell epitope mimic polypeptide of EGFR of the HER family are inserted in a serial form between the 78th amino acid and the 79th amino acid of a hepatitis B core antigen HBcAg so as to form fusion protein which is the combined polypeptide epitope vaccine. The EGFR and HER2 combined polypeptide epitope vaccine of the invention breaks through the limitations of existing single epitope vaccines, and the combined epitope vaccine is providedwith more extensive antineoplastic activity.

The invention belongs to the field of molecular biology and medicine, and specifically discloses an infectious bovine rhinotracheitis virus gD protein antigen epitope polypeptide and an application ofthe polypeptide in preparation of a reagent or a medicament for detecting or treating infectious bovine rhinotracheitis. The invention provides a monoclonal antibody for resisting the infectious bovine rhinotracheitis virus gD protein, and simultaneously the antigen epitope of the infectious bovine rhinotracheitis virus gD protein is screened out as <323>GEPKPGPSPDADRPE<337> (the shortest epitopesequence is 7 amino acid peptide fragments: <323>GEPKPGP<329>). The recombinant protein based on the antigen epitope can specifically be used to detect infectious bovine rhinotracheitis serum; in addition, a small-molecule inhibition drug designed based on the antigen epitope can block virus infection; and meanwhile, the multi-copy repeated epitope vaccine constructed on the basis of the antigenepitope can induce a high-titer gD protein antibody under the assistance of an appropriate adjuvant, and has a relatively high neutralizing antibody titer. The invention lays a foundation for establishing a detection method and researching and developing vaccines for the infectious bovine rhinotracheitis.

The invention discloses an epitope polypeptide combination capable of inducing immunity and application thereof, belongs to the technical field of biology, and aims to carry out molecular design of related vaccines by utilizing immunoinformatics on the basis of epitope analysis optimization. Based on a structural antigen epitope vaccine design strategy, a B cell epitope, a Th epitope and a CTL epitope on a new coronavirus S protein are determined through immunoinformatics to induce a main neutralizing antibody, activate cellular immune response and induce body fluid and cellular immune balance. The epitope vaccine is designed through connection of a molecular adjuvant and candidate antigen epitopes, antigenicity, physicochemical properties, protein secondary structure and tertiary structure modeling of the epitope vaccine are analyzed, vaccine conformation B cell epitopes are analyzed by means of a structural biological tool, and immune response characteristics of the vaccine are verified through molecular docking with TLR4 and immune response simulation stimulation. Information analysis results show that the designed candidate epitope combination has well balanced humoral immune and cellular immune response capabilities.

The invention relates to staphylococcus aureus FnBPA-A protein mimic epitope peptides having immunizing protection, a mimic epitope peptide composition, and applications of the mimic epitope peptides and the mimic epitope peptide composition. Two immunoprotective mimic epitope peptides provided by the invention have the amino acid sequences respectively shown in SEQ ID NO:1 and SEQ ID NO:2, the mimic epitope peptide composition consists of two polypeptides shown in SEQ ID NO:1 and SEQ ID NO:2, and the mass ratio of the polypeptide shown in SEQ ID NO:1 to the polypeptide shown in SEQ ID NO:2 is 2 to 1. Experiment animal immunoprotective tests show that the two mimic epitope peptides can stimulate a body to produce high-level specific antibodies and have a certain degree of immunizing protection; moreover, the mimic epitope peptide composition has the immunoprotective effect on staphylococcus aureus infection better than that of an FnBPA-A holoprotein. Therefore, the mimic epitope peptides and the composition thereof can be used as effective components for development of multi-epitope vaccines of staphylococcus aureus and prevention of cow mastitis caused by staphylococcus aureus.

The invention discloses a bovine viral diarrhea virus (BVDV) E2 multi-epitope fusion peptide and a preparation method thereof. The preparation method comprises the following steps: performing gene synthesis on two respective epitope tandem sequences of optimized E2 proteins such as BVDV-1 and BVDV-2, cloning the sequences to a pET-28a (+) vector, transforming Escherichia coli DH-5alpha, transforming Escherichia coli BL21 from an accurate recombinant vector, performing IPTG inducible expression, and performing Ni-NTA purification, so as to obtain the BVDV E2 multi-epitope fusion peptide. Afterbeing subjected to animal immunization, the E2 multi-epitope fusion peptide is capable of producing a neutralizing antibody of the BVDV, and can be used for research and development of BVDV epitope vaccines; an ELISA (Enzyme-linked Immuno Sorbent Assay) detection kit prepared by utilizing the E2 multi-epitope fusion peptide can be used for BVDV antibody detection of cattle, and has the advantagesof being high in specificity, high in sensitivity, excellent in repeatability and easy to operate.

The invention relates to a B cell immunodominant epitope peptide of staphylococcus aureus enterotoxin B and a preparation method and application thereof, and concretely provides a B cell immunodominant epitope peptide of staphylococcus aureus enterotoxin B. Amino acid sequences of the B cell immunodominant epitope peptide are shown in SEQ ID NO: 17, 35 and 42. Corresponding amino acid sequences of core epitopes of the B cell immunodominant epitope peptide are respectively shown in SEQ ID NO: 48, 54 and 69. According to the preparation method, the B cell immunodominant epitope peptide of the staphylococcus aureus enterotoxin B is assayed by an overlapping peptide binding titration method, so that the screening method is simple, convenient, quick and accurate and is free from omission. The immunodominant epitope peptide does not contain unnecessary or even harmful parts, so that the risk of vaccines prepared from the immunodominant epitope peptide during use is lowered; the immunodominant epitope peptide has a relatively high vaccine application value and can be applied to the preparation of epitope vaccines and/or prevention vaccines of the staphylococcus aureus enterotoxin B.

The invention discloses a method for preparing anti-influenza A virus and novel universal epitope vaccine. The method comprises the following steps: combining a network server and related software to predict functional epitopes of NP, M1 and HA that are related with influenza protection antigen via a bioinformatics method, obtaining a total of 8 epitopes from H1N1, H3N1, H3N2, H5N1, H5N2 subtype CTL epitope and a B-cell epitope, and adding a flexible segment GPGPG between every two of the epitopes to act as linker and naming the linked product as HMN; linking a nucleotide sequence that corresponds to the epitope polypeptide to a plasmid carrier, performing prokaryotic expression, and adding an adjuvant to the purified expressed protein to prepare the vaccine, wherein the vaccine is used to perform immunization in mice. Western blot test proves that the recombinant polypeptide is effective in gene expression and has antigenicity. The T-lymphocyte subset index of the test group is higher than that of the control group in the mice immunization test, and the result indicates that the polypeptide can induce BALC/c mice to generate specific humoral and cellular immune responses specific to the selected epitopes and proves that the polypeptide has strong immunogenicity.

The invention relates to a human metapneumovirus multi-epitope antigen and an application thereof. The human metapneumovirus multi-epitope antigen is formed by combining B cell epitope sequences, Th cell epitope sequences and CTL cell epitope sequences. The epitope sequences in various types are connected in series through connexon. The invention further provides preparing, series connection and expression of human metapneumovirus B cell epitope gene segments, CTL cell epitope gene segments and Th cell epitope gene segments, the human metapneumovirus multi-epitope antigen is prepared, and the cellular-immunity and humoral-immunity activating response level of the human metapneumovirus multi-epitope antigen is evaluated. An evaluation experiment indicates that the human metapneumovirus multi-epitope antigen can activate CTL immunity and Th immunity in cell immunity and can also activate humoral immunity, the certain neutralization effect on hMPV is achieved during an in-vitro experiment, and the human metapneumovirus multi-epitope antigen can be used for developing epitope vaccine, establishing an immunology diagnosis method, researching disease epidemiology, carrying out hMPV infection immunity treatment and the like.

The invention provides a novel chimeric flagellin adjuvant of a helicobacter pylori multi-epitope vaccine. An active ingredient of the novel chimeric flagellin adjuvant of the helicobacter pylori multi-epitope vaccine is a polypeptide chain which mainly consists of regions D0 and D1 of salmonella typhimurium flagellin Flic, and regions D2 and D3 of helicobacter pylori flagellin F1aA. A nucleotide sequence of the protein adjuvant is synthesized through a PCR (polymerase chain reaction) technology, expressed in escherichia coli by utilizing an expression vector, and the adjuvant protein is obtained after protein purification.

The invention discloses a eukaryotic expression method of a fish viral hemorrhagic septicemia virus G gene. The method includes the following steps of (1) gene synthesis of a main antigenic domain optimized by codons, (2) construction of a reconstructed baculovirus transfer vector, (3) construction of shuttle plasmids and (4) analysis and identification of reconstructed Bacmid transfection and expression products. By means of the method, efficient expression of the G protein antigenic domain in a Bac-to-Bac baculovirus system; the activity of the expression protein is primarily identified and analyzed through Western blotting, it is proved that the expression protein has immunogenicity, and a foundation is provided for further epitope vaccine development and VHSV molecular diagnosis technology establishment.

The invention discloses an American-type PRRSV N protein antigenic epitope and applications thereof, and aims to solve the technical problem of insufficient research on PRRSV N protein cell epitopes.The invention designs a short peptide, and the amino acid sequence of the short peptide is as shown in SEQ NO.1 or is an amino acid sequence which is derived from the amino acid sequence as shown in the SEQ ID NO.1 and has the same function. The American-type PRRSV N protein antigenic epitope is screened, and comprises the amino acid sequence of the short peptide. The short peptide or the American-type PRRSV N protein antigenic epitope are applied in preparing an antibody for preventing and/or treating American-type PRRSV. The invention provides a novel N-protein antigenic epitope, completes the identification of the epitope, improves the epitope map of the N protein, lays a foundation for the research of American-type PRRSV cross-protective epitope vaccines, and has great significance fordifferentiated detection on American-type PRRSV and European-type PRRSV.

The invention belongs to the technical field of biotechnology, and particularly discloses an echinococcus granulosus EgTeg and EgFABP1 multi-epitope vaccine and application. Theechinococcus granulosus EgTeg and EgFABP1 multi-epitope vaccine comprises a CD8 + T cell epitope, a CD4 + T cell epitope and a B cell epitope of an EgTeg protein and an EgFABP1 protein. The invention further discloses a screening method and application of the multi-epitope vaccine, and compared with a vaccine obtained by a traditional antigen epitope screening method, after the EgTeg and EgFABP1 multi-epitope vaccine provided by the invention is inoculated, the wet weight of the echinococcus granulosus cyst in a mouse body infected by echinococcus granulosus protoscolex can be effectively reduced; and the screening time and economic cost are low, the experimental process is simplified, and the echinococcus granulosus EgTeg and EgFABP1 multi-epitope vaccine is suitable for wide screening, popularization and application of the antigen epitopes.